Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis dosed the first patient in the Phase 3 ASPENOVA trial evaluating azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer. The confirmatory study is designed to support full approval and will enroll approximately 420 patients to compare the WEE1 inhibitor against standard-of-care chemotherapy.
Key figures
- Drug Name
- azenosertib
- Phase Of Trial
- Phase 3
- Azenosertib dose
- 400mg QD 5:2
- Aspnova enrollment
- approximately 420
- Denali readout timing
- year-end 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.